newsfilter
← Latest News
GlobeNewswire·

Cogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Cogent Biosciences' independent Compensation Committee approved inducement equity grants for 10 new employees on September 25, 2025.
  • The grants, effective September 29, 2025, comprise 299,200 nonqualified stock options for the purchase of common stock.
  • The awards comply with Nasdaq Listing Rule 5635(c)(4) & each option has a 10-year term with an exercise price equal to the closing stock price on the grant date.
  • The vesting schedule includes 25% vesting on the one-year anniversary, with the remainder vesting in equal monthly installments over the next 36 months contingent on continued employment.
  • The company is developing bezuclastinib, a selective tyrosine kinase inhibitor targeting the KIT D816V mutation associated with systemic mastocytosis & KIT exon 17 mutations in gastrointestinal stromal tumors (GIST).
  • Additional programs include a Phase 1 study of an FGFR2/3 inhibitor & a portfolio of targeted therapies for ErbB2, PI3Kα, & KRAS mutations.
  • Cogent Biosciences is headquartered in Waltham, Massachusetts & Boulder, Colorado.